Search results
Results from the WOW.Com Content Network
SCB-2019 is a protein subunit COVID-19 vaccine developed by Clover Biopharmaceuticals using an adjuvant from Dynavax technologies. [2] Positive results of Phase I trials for the vaccine were published in The Lancet [ 3 ] and the vaccine completed enrollment of 29,000 participants in Phase II/III trials in July 2021. [ 4 ]
A conjugate vaccine is a type of subunit vaccine which combines a weak antigen with a strong antigen as a carrier so that the immune system has a stronger response to the weak antigen. Vaccines are used to prevent diseases by invoking an immune response to an antigen, part of a bacterium or virus that the immune system recognizes. [ 2 ]
Vaccine Excipients Adenovirus vaccine: This list refers to the type 4 and type 7 adenovirus vaccine tablets licensed in the US: Acetone, alcohol, anhydrous lactose, castor oil, cellulose acetate phthalate, dextrose, D-fructose, D-mannose, FD&C Yellow #6 aluminium lake dye, fetal bovine serum, human serum albumin, magnesium stearate, micro crystalline cellulose, plasdone C, Polacrilin potassium ...
Pharmaceutical compound S-268019 Vaccine description Target SARS-CoV-2 Vaccine type Protein subunit Clinical data Routes of administration Intramuscular Identifiers CAS Number 2696247-53-5 Part of a series on the COVID-19 pandemic Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom. COVID-19 (disease) SARS-CoV-2 (virus) Cases Deaths Timeline ...
ZF2001, trade-named Zifivax or ZF-UZ-VAC-2001, is an adjuvanted protein subunit COVID-19 vaccine developed by Anhui Zhifei Longcom in collaboration with the Institute of Microbiology at the Chinese Academy of Sciences. [2] [3] The vaccine candidate is in Phase III trials with 29,000 participants in China, Ecuador, Malaysia, Pakistan, and ...
The Medicago method to manufacture CoVLP was a "molecular farming" technology regarded as rapid, low-cost, and safe. [8] [11] It was proposed specifically for production of COVID-19 vaccines. [12] [13] In February 2022, Health Canada authorized use of CoVLP for preventing COVID-19 infection in adults 18 to 64 years old. [3] The authorization ...
The Sinopharm WIBP COVID-19 vaccine, also known as WIBP-CorV, [2] [3] is one of two inactivated virus COVID-19 vaccines developed by Sinopharm. Peer-reviewed results show that the vaccine is 72.8% effective against symptomatic cases and 100% against severe cases (26 cases in vaccinated group vs. 95 cases in placebo group). [ 4 ]
Pharmaceutical compound Sinopharm CNBG COVID-19 vaccine Vaccine description Target SARS-CoV-2 Vaccine type Protein subunit Clinical data Routes of administration Intramuscular Legal status Legal status Full list of Sinopharm NVSI authorizations Identifiers CAS Number 2503126-65-4 Part of a series on the COVID-19 pandemic Scientifically accurate atomic model of the external structure of SARS ...